Precision Neuroscience
PrivateLast Round
Series D
Sep 24, 2026
Est. Valuation
$1B
Total Funding Raised
$405M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Precision Neuroscience operates in Healthcare & Life Sciences and is based in New York City, New York. Its latest recorded funding round was a Series D round in September 2026.
Precision Neuroscience is a neurotechnology company that develops minimally invasive brain-computer interface technology aimed at delivering effective treatments for patients with neurological disorders by facilitating direct connections between the human brain and artificial intelligence.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Precision Medicine
Business Model
B2B
Customer Profile
Hardware Sales, Data as a Service
AI Layer
Application
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Precision Neuroscience Comparables
Compare Precision Neuroscience with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Synchron | 86% | |
| Neuralink | 84% | |
| Paradromics | 83% |
For institutional investors. Book with your work email.
Precision Neuroscience Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Sep 24, 2026 | ||||
| Strategic | Nov 5, 2025 | ||||
| Series C | Dec 16, 2024 | ||||
| Series B | Jan 25, 2023 | ||||
| Series A | May 25, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Precision Neuroscience Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Forepont Capital Partners | Series B |
| Pershing Square Capital Management, L.P. | Series D |
| B Capital Group | Series D |
| Steadview Capital | Series B, Series C, Series A |
| SCI Ventures | Strategic |
| Korea Investment Partners | Series D |
| Mirae Asset | Series D |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Sep 24, 2026
$250M round with participation from ARK Investment Management and Mubadala Capital.
- Jun 16, 2026
Monthly visitors increased 81% MoM, reaching 23K.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingNov 1, 2026
Precisionneuro is developing a minimally invasive cortical interface that reads neural signals at high resolution through a thin-film electrode array placed on the brain’s surface via a comparatively small incision.
- partners_withOct 29, 2026
On Oct 21st '26, Precisionneuro partners with Cleveland Clinic Abu Dhabi LLC under a two-year memorandum of understanding to evaluate the Layer 7 cortical interface in collaborative clinical research, including neural mapping, monitoring, training, knowledge exchange, and potential joint technology development, in United Arab Emirates.
- hiresOct 15, 2026
Precisionneuro hires Katherine Neuenfeldt as senior vice president, commercial strategies, following her leadership of the U.S. launch and market access strategy for Nevro’s Senza spinal cord stimulation system, in New York on Oct 15th '26.
- is_developingOct 8, 2026
Precisionneuro is developing an implantable brain-computer interface to restore movement, speech, and communication for people with serious neurological conditions, including paralysis caused by spinal cord injury or stroke and neurodegenerative disorders such as ALS.
- has_valuationSep 24, 2026
The latest financing values Precisionneuro at more than $1B in New York and brings its total funding to $430 million.
For institutional investors. Book with your work email.
Precision Neuroscience Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Precision Neuroscience's valuation, stock price, and market status.
Is Precision Neuroscience a public or private company?
Precision Neuroscience is a private company.
What is the current stock price of Precision Neuroscience?
Precision Neuroscience is a private company, so its shares have no public market price. Caplight tracks Precision Neuroscience's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Precision Neuroscience worth (valuation)?
Precision Neuroscience's valuation is estimated at $1.0B based on funding round data.
Can I buy Precision Neuroscience stock?
Precision Neuroscience shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Precision Neuroscience's last funding round?
Precision Neuroscience's most recent funding round was Series D on September 24, 2026.
Who are the main investors in Precision Neuroscience?
Key investors in Precision Neuroscience include Forepont Capital Partners, Pershing Square Capital Management, L.P., Steadview Capital, SCI Ventures, B Capital Group.
Will Precision Neuroscience IPO soon?
No public IPO plans have been announced for Precision Neuroscience.
How can I track Precision Neuroscience secondary market activity?
Caplight tracks bids, offers, and trades in Precision Neuroscience's shares on secondary markets.